Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

Core Viewpoint - Ipsen has successfully completed the acquisition of ImCheck Therapeutics, a private French biotechnology company focused on next-generation immuno-oncology therapies [1] Company Overview - Ipsen is a global biopharmaceutical company dedicated to developing transformative medicines in three main therapeutic areas: Oncology, Rare Disease, and Neuroscience [2] - The company has nearly 100 years of development experience and operates global hubs in the U.S., France, and the U.K., with teams in over 40 countries [2] - Ipsen's medicines are available to patients in more than 100 countries, supported by both internal and external innovation [2] Stock Information - Ipsen is listed on Euronext under the ticker IPN and has a Sponsored Level I American Depositary Receipt program in the U.S. under the ticker IPSEY [3]